David Xiong is a Dermatology physician affiliated with University Hospitals of Cleveland. OpenAlex indexes 38 publications with 1,329 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2049 E 100th St Dept Of
Cleveland, OH 441062104
Telephone
216-844-3178Provider last certified this registry record 2 Aug 2024.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
53.3%Azole Antifungal40.2%Ketoconazole100%Part D≥34 patientsLincosamide Antibacterial13.1%Clindamycin Phosphate100%Part D≥12 patientsDermatology
31.1%Corticosteroid31.1%Triamcinolone Acetonide100%Part D≥27 patientsSensory organs
15.6%Corticosteroid15.6%Clobetasol Propionate100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and outcomes of invasive cutaneous melanoma: A retrospective national cohort study
Journal of the American Academy of Dermatology
2023 - Factors and outcomes associated with treatment delays in rare cutaneous adnexal tumors: A population-based retrospective cohort study
Journal of the American Academy of Dermatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lederman, MD
University Hospitals of Cleveland
Anthony Furlan
University Hospitals of Cleveland
Joseph Sabik, MD
University Hospitals of Cleveland
Hans Luders
University Hospitals of Cleveland
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”